Last reviewed · How we verify

Dexamethasone+ Bupivacaine

Ain Shams University · FDA-approved active Small molecule

Dexamethasone reduces inflammation and immune response while bupivacaine provides local anesthesia by blocking nerve conduction.

Dexamethasone reduces inflammation and immune response while bupivacaine provides local anesthesia by blocking nerve conduction. Used for Local anesthesia with anti-inflammatory effect for regional anesthesia and pain management, Periarticular or perineural injection to reduce postoperative pain and inflammation.

At a glance

Generic nameDexamethasone+ Bupivacaine
SponsorAin Shams University
Drug classCorticosteroid + Local anesthetic combination
TargetGlucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)
ModalitySmall molecule
Therapeutic areaPain management, Anesthesia, Inflammation
PhaseFDA-approved

Mechanism of action

Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production. Bupivacaine is a local anesthetic that blocks sodium channels in nerve membranes, preventing action potential propagation. Together, this combination provides both local pain relief and anti-inflammatory effects at the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: